Exelixis EVP Haley Patrick J. sells $1.5 million in stock

Exelixis EVP Haley Patrick J. sold 34,387 shares on May 20, 2025, at an average price of $44.06, totaling approximately $1.5 million, while retaining 412,072 shares. This transaction follows Exelixis' strong Q1 2025 results, driven by Cabometyx sales, leading to raised full-year revenue guidance to $2.25-$2.35 billion and positive analyst target revisions from TD Cowen, Lucid Capital Markets, and Stifel; RBC Capital Markets maintained an Outperform rating, citing a promising pipeline and upcoming clinical trial results.

Analysis

Exelixis, Inc. (NASDAQ:EXEL) has demonstrated significant positive momentum, underscored by a 104% stock return over the past year and an "EXCELLENT" financial health rating. This performance is supported by strong first-quarter 2025 financial results, where revenues reached approximately $555.4 million, surpassing consensus estimates, largely driven by its flagship cancer drug, Cabometyx. Consequently, Exelixis raised its full-year revenue guidance to a range of $2.25 to $2.35 billion. Amidst this, Haley Patrick J., Executive Vice President of Commercial, sold 34,387 shares at a weighted average price of $44.06, totaling around $1.5 million on May 20, 2025, yet retains a substantial direct holding of 412,072 shares. Analyst sentiment remains broadly positive, with TD Cowen increasing its price target to $44 (Buy), Stifel to $38, and RBC Capital Markets maintaining an Outperform rating with a $40 target, all citing robust Cabometyx sales and pipeline potential. Lucid Capital Markets offered a more conservative target of $37 with a Neutral rating. The company's confidence is further reflected in its ongoing share repurchase program, with $505 million remaining, and InvestingPro analysis suggests the stock is currently undervalued, supported by a perfect Piotroski Score of 9. Promising clinical trial results for zanzalintinib in kidney cancer also indicate potential for further growth within Exelixis's oncology pipeline.

Key Decisions for Investors

• Investors should view the executive share sale in the context of the substantial remaining ownership and powerful company performance, recognizing it may not signal a negative outlook.
• The strong Q1 2025 earnings, upwardly revised full-year revenue guidance, robust Cabometyx sales, positive analyst revisions, and ongoing share repurchase program collectively suggest a fundamentally sound investment case.
• Monitor upcoming clinical trial results for zanzalintinib and other pipeline developments, as these could serve as significant catalysts, especially considering the stock's current undervaluation indicated by InvestingPro and its perfect Piotroski Score.